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injection was monitored on real-time ultrasound using the 
probe on the endoscope. Patients were monitored for two 
hours before discharge.  
Daily cone beam CT (CBCT) images and 2D kV fluoroscopy 
(FS) images at fractions 2, 16 and 30 were acquired for setup 
and evaluation of marker visibility.  
Safety visits were planned twice during the RT course. 
 
Results: 15 patients were included. A total of 35 markers 
were injected, 1-3 markers per patient, 0.10-0.30 mL per 
injection.  
The marker injections were performed 9-27 days before start 
of RT  
No pneumothorax, haemorrhage or other serious 
complications to the marker injection were observed during 
or after the procedure.  
29 of 35 placed markers were available for evaluation; 2 
markers disappeared and one dispersed into a tumour cavity.  
Another three markers were injected in two patients who 
subsequently did not receive RT; one patient died (not 
related to the marker) and one patient developed metastatic 
disease prior to start of RT.  
All 29 examined markers remained stable in position relative 
to original injection site (based on visual assessment) and 
were visible on planning CT, CBCT and FS images throughout 
the treatment course (fig.1).  
27 of 29 markers were usable for image registration between 
planning CT and CBCT.  
No marker related adverse events were seen during the RT 
period. 
 
 
Conclusion: The liquid fiducial marker is a safe and clinically 
useful alternative to solid metal fiducial markers for IGRT of 
patients with NSCLC and may also be a good alternative for 
use in IGRT of other solid tumours. 
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Purpose or Objective: Standard of care for patients with 
inoperable, locally advanced non-small-cell lung cancer 
(NSCLC) consists in combined radiochemotherapy (RCT) with 
curative intent. Ideally, radiotherapy planning will be 
performed based on F18-FDG-PET/CT. Additionally, there is 
great interest in using the biological signal from PET/CT for 
assessment of treatment response and outcome prediction. 
Hypothetically, PET/CT may serve as basis for treatment 
modification such as dose escalation of radiotherapy for poor 
responders to RCT. The objective of the presented work was 
the evaluation of the early primary tumor (PT) response 
during RCT by means of response (R)-PET/CTs during and 
shortly after radiotherapy and its correlation with survival. 
 
Material and Methods: Between 2011 – 2015, 39 patients 
with locally advanced NSCLC undergoing conventionally 
fractionated (2 Gy/day) RCT were prospectively scheduled 
for three whole-body PET/CT-scans (a radiotherapy planning 
(RP) PET/CT, a first response PET/CT (1R-PET/CT) 2 weeks 
after start of RCT and a second response PET/CT (2R-PET/CT) 
within one week after end of RCT. FDG-uptake of the PT was 
measured semiquantitatively by means of the maximum 
standardized uptake value (SUVmax). SUVmax measurements 
were compared using PERCIST 1.0 criteria*. Here, a response 
to treatment is defined by a decline of SUVmax of at least 
30% (partial metabolic response, PMR). * Wahl RL, et al.: 
From RECIST to PERCIST: Evolving Considerations for PET 
Response Criteria in Solid Tumors, JNM, Vol. 50, No. 5 
(Suppl), May 2009 
 
Results: 39 patients (33% female, 67% male) with a NSCLC 
(59% SCC, 31% adenocarcinoma and 10% other NSCLC) in 
UICC-stage IIa (5%), IIIa (51%) und IIIb (44%) received an 
average total dose of median 68 (58-76) Gy during a median 
duration of 49 (39-66) irradiation days. Median GTV size was 
58 (15-923) ml. SUVmax was median 14 (5.5-28.3) in the RP-
PET/CT median 15 (2-37) days before start of irradiation. 33 
patients had a 1R-PET/CT median 15 (13-29) days after start 
of irradiation and at median 22 (16-40) Gy, with a SUVmax of 
median 10.5 (3.4-23.7)). 36 patients had a 2R-PET/CT median 
4.5 (4 days before, 15) days after end of irradiation, with a 
SUVmax of median 5.45 (1.4-14.3). A PMR was seen in 14/33 
(42%) patients in the 1R-PET/CT (PMR1) (compared to the RP-
PET/CT), and in 22/30 (73%) patients in the 2R-PET/CT 
(PMR2) (compared to the 1R-PET/CT). 9/29 (31%) patients 
reached both a PMR1 and a PMR2 (double PMR), none of these 
patients experienced a PT-progression during a median follow 
up of 18 (1.4-53) months after end of irradiation. The 2-year-
overall survival rate was 75% as opposed to 54% without a 
double PMR. 
 
Conclusion: These preliminary data imply that a double PMR 
measured in response PET/CTs scheduled during and at the 
end of RCT for NSCLC is associated with a prolonged overall 
survival rate. 
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Purpose or Objective: Our hypothesis is that NSCLC patients 
and malignant pleural mesothelioma (MPM) patients treated 
with thoracic post-operative RT (PORT) are more prone to 
develop lung toxicity compared to non-surgical NSCLC RT 
patients. Main objectives are: 1) To quantify the differences 
in terms of CT lung density changes after PORT for NSCLC and 
MPM vs. non-surgical RT patients; and 2) To evaluate the 
correlation between CT lung density changes, dosimetric 
factors and clinical symptoms (dyspnea). 
 
Material and Methods: Two groups of patients were 
analyzed: a) SURGICAL GROUP (n=27): stage I-III resectable 
MPM treated with extrapleural pneumonectomy (EPP) and 
PORT (n=22) and stage I-III NSCLC treated with 
pneumonectomy and PORT (n=5); b) NON-SURGICAL GROUP 
(n=35): stage I-IV NSCLC treated with chemo-radiotherapy. 
